Interleukin-2 family cytokines: Potential for therapeutic immunoregulation

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 5, 2005, Pages 521-554

  Dumont, Francis J ^a  

^a Medor Consulting   (United States)

Author keywords

c chain; Autoimmune disease; B cell; Cytokine; IL 2 family cytokines; Immune deviation; Immunostimulation; Immunosuppression; Inflammation; Interleukin; Jak3 kinase; Lymphocyte; Natural killer (NK) cell; T cell; Transplant rejection

Indexed keywords

3 (4 PYRIDINYLAMINO) 1H INDOLE 2 CARBOXYLIC ACID; 4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; ADENOVIRUS VECTOR; ALBULEUKIN; ALTRAKINCEPT; AMG 714; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BASILIXIMAB; BAY 19 9996; BAY 50 4798; BENZOFURAN DERIVATIVE; BETA INTERFERON; CELL SURFACE RECEPTOR; CRB 15; CYCLOSPORIN A; CYTOKINE; DACLIZUMAB; DENDRITIC CELL VACCINE; EMD 273063; EMD 273066; GLOBULAR PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIDAZO[2,1 B]BENZOTHIAZOLE DERIVATIVE; INDOLE DERIVATIVE; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR ANTIBODY; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 4 ANTIBODY; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; INTERLEUKIN 9; JANUS KINASE; JANUS KINASE 3; JANUS KINASE 3 INHIBITOR; LEUVECTIN; MEDI 528; MONOCLONAL ANTIBODY; NC 1153; POLYKETIDE; PROTEIN SUBUNIT; PYRROLO[2,3 D]PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; RAPAMYCIN; RECOMBINANT INTERLEUKIN 2; TACROLIMUS; TETRAHYDROQUINOLINE DERIVATIVE; TMC 264; TRASTUZUMAB; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ALPHA HELIX; ANEMIA; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; BONE MARROW TOXICITY; CELL LINEAGE; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; CONFUSION; CYTOKINE PRODUCTION; DRUG BINDING SITE; DRUG DESIGN; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENZYME MECHANISM; GENE MUTATION; GRAFT REJECTION; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; INTRACELLULAR SPACE; ISCHEMIA; LYMPHOCYTE SUBPOPULATION; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; NEPHROTOXICITY; NONHUMAN; OLIGURIA; PATENT; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION; X CHROMOSOME LINKED DISORDER;

EID: 19044370832     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.5.521     Document Type: Review

References (298)

1. OZAKI K, LEONARD WJ: Cytokine and cytokine receptor pleiotropy and redundancy. J. Biol. Chem. (2002) 277:29355-29358.
2. GAFFEN SL, LIU KD: Overview of interleukin-2 function, production and clinical applications. Cytokine (2004) 28:109-123.
3. BENCZIK M, GAFFEN SL: The interleukin (IL)-2 family cytokines: survival and proliferation signaling pathways in T lymphocytes. Immunol. Invest. (2004) 33:109-142.
4. ROZWARSKI D, GRONENBORN A, CLORE G et al.: Structural comparisons among the short-chain helical cytokines. Structure (1994) 2:159-173.
5. LEONARD WJ: Cytokines and immunodeficiency diseases. Nat. Rev. Immunol (2001) 1:200-208.
6. EMERSON SD, PALERMO R, LIU CM et al.: NMR characterization of interleukin-2 in complexes with the IL-2Rα receptor component, and with low molecular weight compounds that inhibit the IL-2/IL-Rα interaction. Protein Sci. (2003) 12:811-822.
7. D'SOUZA WN, LEFRANCOIS L: An in-depth evaluation of the production of IL-2 by antigen-specific CD8 T cells in vivo. Eur. J. Immunol. (2004) 34:2977-2985.
8. FEAU S, FACCHINETTI V, G RANUCCI F et al.: Dendritic cell-derived IL2 production is regulated by IL-15 both in humans and mice. Blood (2005) 105:697-702.
9. KIM HP, LEONARD WJ: The basis for TCR-mediated regulation of the IL-2 receptor α chain gene: role of widely separated regulatory elements. EMBO J. (2002) 21:3051-3059.
10. KIM HP, KELLY J, LEONARD WJ: The basis for IL-2-induced IL-2 receptor α chain gene regulation: importance of two widely separated IL-2 response elements. Immunity (2001) 15:159-172.
11. GAFFEN SL: Signaling domains of the interleukin-2 receptor. Cytokine (2001) 14:63-77.
12. LIN JX, LEONARD WJ: The role of Stat5a and Stat5b in signalling by the IL-2 family cytokines. Oncogene (2000) 19:2566-2576.
13. LINDEMANN MJ, BENCZIK M, GAFFEN SL: Anti-apoptotic signaling by the interleukin-2 receptor reveals a function for cytoplasmic tyrosine residues within the common γ (γc) receptor subunit. J. Biol. Chem. (2003) 278:10239-10249.
14. CORNISH AL, CHONG MM, DAVEY GM et al.: Suppressor of cytokine signaling-1 regulates signaling in response no interleukin-2 and other γc-dependent cytokines in peripheral T cells. J. Biol. Chem. (2003) 278:22755-22761.
15. MALEK TR, YU A, SCIBELLI P, LICHTENHELD MG, CODIAS EK: Broad programming by IL-2 receptor signaling for extended growth to multiple cytokines and functional maturation of antigen-activated T cells. J. Immunol. (2001) 166:1675-1683.
16. BAUER DE, HARRIS MH, PLAS DR et al.: Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand. FASEB J. (2004) 18:1303-1305.
17. BECKNELL B, CALIGIURI MA: Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv. Immunol. (2005) 86:209-239.
18. D'SOUZA WN, LEFRANCOIS L: IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion. J. Immunol. (2003) 171:5727-5735.
19. DOOMS H, KAHN E, KNOECHEL B, ABBAS AK: IL-2 induces a competitive survival advantage in T lymphocytes. J. Immunol. (2004) 172:5973-5979.
20. MALEK TR, BAYER AL: Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. (2004) 4:665-674.
21. WALDMANN TA, DUBOIS S, TAGAYA Y: Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity (2001) 14:105-110.
22. MURPHY KM, REINER SL: The lineage decisions of helper T cells. Nat. Rev. Immunol. (2002) 2:933-944.
23. H2 responses for immunotherapy. Expert Opin. Ther. Patents (2002) 12:341-367.
24. JARNICKI AG, FALLON PG: T helper type-2 cytokine responses: potential therapeutic targets. Curr. Opin. Pharmacol. (2003) 3:449-455.
25. KHODOUN MV, OREKHOVA T, POTTER C, MORRIS S, FINKELMAN FD: Basophils initiate IL-4 production during a memory T-dependent response. J. Exp. Med. (2004) 200:857-870.
26. SEINO K, TANIGUCHI M: Functional roles of NKT cell in the immune system. Front Biosci. (2004) 9:2577-2587.
27. ATAMAS SP, CHOI J, YUROVSKY VV, WHITE B: An alternative splice variant of human IL-4, IL-4δ2, inhibits IL-4-stimulated T cell proliferation. J. Immunol. (1996) 156:435-441.
28. VASILIEV AM, VASILENKO RN, KULIKOVA NL et al.: Structural and functional properties of IL-4δ2, an alternative splice variant of human IL-4. J. Proteome Res. (2003) 2:273-281.
29. LI-WEBER M, KRAMMER PH: Regulation of IL-4 gene expression by T cells and therapeutic perspectives. Nat. Rev. Immunol. (2003) 3:534-543.
30. ELSER B, LOHOFF M, KOCK S et al.: IFN-γ represses IL-4 expression via IRF-1 and IRF-2. Immunity (2002) 17:703-712.
31. NELMS K, KEEGAN AD, ZAMORANO JJ, PAUL WE: The IL-4 receptor: signaling mechanisms and biologic functions. Ann. Rev. Immunol. (1999) 17:701-738.
32. MUELLER TD, ZHANG JL, SEBALD W, DUSCHL A: Structure, binding, and antagonists in the IL-4/IL-13 receptor system. Biochim. Biophys. Acta (2002) 1592:237-250.
33. HAGE T, SEBALD W, REINEMER P: Crystal structure of the interleukin-4/eceptor α chain complex reveals a mosaic binding interface. Cell (1999) 97:271-281.
34. OBER C, LEAVITT SA, TSALENKO A et al.: Variation in the interleukin 4-receptor gene confers susceptibility to asthma and atopy in ethnically diverse populations. Am J. Hum. Genet. (2000) 66:517-526.
35. RISMA KA, WANG N, ANDREWS RP et al.: V75R576 IL-4 receptor is associated with allergic asthma and enhanced IL-4 receptor function. J. Immunol. (2002) 169:1604-1610.
36. BEGHE B, BARTON S, RORKE S et al.: Polymorphisms in the interleukin-4 and interleukin-4 receptor α chain genes confer susceptibility to asthma and atopy in a Caucasian population. Clin. Exp. Allergy (2003) 33:1111-1117.
37. XIAO H, YIN T, WANG XY et al.: Specificity of interleukin-2 receptor γ chain superfamily cytokines is mediated by insulin receptor substrate-dependent pathway. J. Biol. Chem. (2002) 277:8091-8098.
38. CHATILA TA: Interleukin-4 receptor signaling pathways in asthma pathogenesis. Trends Mol. Med. (2004) 10:493-499.
39. H2 responses even in the combined absence of IL-5, IL-9 and IL-13. Immunity (2002) 17:7-17.
40. FEAR DJ, MCCLOSKEY N, O'CONNOR B, FELSENFELD G, GOULD HJ: Transcription of Ig germline genes in single human B cells and the role of cytokines in isotype determination. J. Immunol. (2004) 173:4529-4538.
41. LEE YW, EUM SY, CHEN KC, HENNIG B, TOBOREK M: Gene expression profile in interleukin-4-stimulated human vascular endothelial cells. Mol. Med. (2004) 10:19-27.
42. DAUER M. OBERMAIER B, HERTEN J et al.: Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J. Immunol. (2003) 170:4069-4076.
43. + myeloid dendritic cell subset. J. Cell Sci. (2004) 117:3435-3445.
44. STRAIT RT, MORRIS SC, SMILEY K, URBAN JF, FINKELMAN FD: IL-4 exacerbates anaphylaxis. J. Immunol. (2003) 170:3835-3842.
45. H2 cytokine basis of asthma. Trends Pharmacol. Sci. (2004) 25:244-248.
46. SINGH RR: IL-4 and many roads to lupus-like autoimmunity. Clin. Immunol. (2003) 108:73-79.
47. FRY TJ, MACKALL CL: Interleukin-7: from bench to clinic. Blood (2002) 99:3892-3904.
48. COSENZA L, ROSENBACH A, WHITE JV, MURPHY JR, SMITH T: Comparative model building of interleukin-7 using interleukin-4 as a template: a structural hypothesis that displays a typical surface chemistry in helix D important for receptor activation. 2000 (2000) 9:916-926.
49. WEITZMANN MN, CENCI S, RIFAS L, BROWN C, PACIFICI R: Interleukin-7 stimulates osteoclast formation by upregulating the T-cell production of soluble osteoclastogenic cytokines. Blood (2000) 96:1873-1878.
50. OSHIMA S, NAKAMURA T, NAMIKI S et al.: Interferon regulatory factor-1 (IRF-1) and IRF-2 distinctively up-regulate gene expression and production of interleukin-7 in human intestinal epithelial cells. Mol. Cell. Biol. (2004) 24:6298-6310.
51. NAPOLITANO LA, GRANT RM, DEEKS SG et al.: Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat. Med. (2001) 7:73-79.
52. BRADLEY LM, HAYNES L, SWAIN SL: IL-7: maintaining T-cell memory and achieving homeostasis. Trends Immunol. (2005) 26:172-176.
53. PONCHEL F, VERBURG RJ, BINGHAM SJ et al.: Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. Arthritis Res. Ther. (2005) 7:R80-R92.
54. HOFMEISTER R, KHALED AR, BENBERNOU N et al.: Interleukin-7: physiological roles and mechanisms of action. Cytokine Growth Factor Rev. (1999) 10:41-60.
55. SOUMELIS V, LIU YJ: Human thymic stromal lymphopoietin: a novel epithelial cell-derived cytokine and a potential key player in the induction of allergic inflammation. Springer Seminars in Immunopathology. (2004) 25:325-333.
56. MUNITIC I, WILLLAMS JA, YANG Y et al.: Dynamic regulation of IL-7 receptor expression is required for normal thymopoiesis. Blood (2004) 104:4165-4172.
57. + mucosal T cells in mice. Am. J. Physiol. Gastrointest. Liver Physiol. (2005) 288:G745-G754.
58. + memory T cell subsets. Proc. Natl. Acad. Sci. USA (2004) 101:5610-5615.
59. XUE HH, KOVANEN PE, PISE-MASISON CA et al.: IL-2 negatively regulates IL-7 receptor α chain expression in activated T lymphocytes. Proc. Natl. Acad. Sci. USA (2002) 99:13759-13764.
60. PARK JH, YU Q, ERMAN B et al.: Suppression of IL7Rα transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival. Immunity (2004) 21:289-302.
61. DEKOTER RP, LEE HJ, SINGH H: PU.1 regulates expression of the interleukin-7 receptor in lymphoid progenitors. Immunity (2002) 16:297-309.
62. XUE HH, BOLLENBACHER J, ROVELLA V et al.: GA binding protein regulates interleukin-7 receptor α-chain gene expression in T cells. Nat. Immunol. (2004) 5:1036-1044.
63. FRANCHIMONT D, GALON J, VACCHIO MS et al.: Positive effects of glucocorticoids on T cell function by upregulation of IL-7 receptor α. J. Immunol. (2002) 168:2212-2218.
64. KANG J, DER SD: Cytokine functions in the formative stages of a lymphocyte's life. Curr. Opin. Immunol. (2004) 16:180-190.
65. JIANG Q, LI WQ, HOFMEISTER RR et al.: Distinct regions of the interleukin-7 receptor regulate different Bcl2 family members. Mol. Cell. Biol. (2004) 24:6501-6513.
66. LI WQ, JIANG Q, KHALED AR, KELLER JR, DURUM SK: Interleukin-7 inactivates the pro-apoptotic protein Bad promoting T cell survival. J. Biol. Chem. (2004) 279:29160-29166.
67. ROIFMAN CM, ZHANG J, CHITAYAT D, SHARFE N: A partial deficiency of interleukin-7R α is sufficient to abrogate T-cell development and cause severe combined immunodeficiency. Blood (2000) 96:2803-2807.
68. EL KASSAR N, LUCAS PJ, KLUG DB et al.: A dose effect of IL-7 on thymocyte development. Blood (2004) 104:1419-1427.
69. NAPOLITANO LA, STODDART CA, HANLEY MB, WIEDER E, MCCUNE JM: Effects of IL-7 on early human thymocyte progenitor cells in vitro and in SCID-hu Thy/Liv mice. J. Immunol. (2003) 171:645-654.
70. HUANG J, MUEGGE K: Control of chromatin accessibility for V(D)J recombination by interleukin-7. J. Leukoc. Biol. (2001) 69:907-911.
71. OKAMOTO Y, DOUEK DC, MCFARLAND RD, KOUP RA: Effects of exogenous interleukin-7 on human thymus function. Blood (2002) 99:2851-2858.
72. + α-chain variable gene segment 24 (Vα24) natural killer T cells in the early human fetal thymus is regulated by IL-7. Proc. Natl. Acad. Sci. USA (2004) 101:7058-7063.
73. - subsets of Vα24-invariant natural killer T cells in humans. Blood (2004) 104:4150-4156.
74. TAN JT, DUDL E, LEROY E et al.: IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc. Natl. Acad. Sci. USA (2001) 98:8732-8737.
75. SEDDON B, TOMLINSON P, ZAMOYSKA R: Interleukin-7 and T cell receptor signals regulate homeostasis of CD4 memory cells. Nat. Immunol. (2003) 4:680-686,
76. LI J, HUSTON G, SWAIN SL: IL-7 promotes the transition of CD4 effectors to persistent memory cells. J. Exp. Med. (2003) 198:1807-1815.
77. KONDRACK RM, HARBERTSON J, TAN JT et al.: Interleukin 7 regulates the survival and generation of memory CD4 cells. J. Exp. Med. (2003) 198:1797-1806.
78. + T cell memory. Proc. Natl. Acad. Sci. USA (2004) 101:9357-9362.
79. SEDDON B, ZAMOYSKA R: TCR and IL-7 receptor signals can operate independently or synergize to promote lymphopenia-induced expansion of naive T cells. J. Immunol. (2002) 169:3752-3759.
80. STOCKINGER B, BARTHLOTT T, KASSIOTIS G: The concept of space and competition in immune regulation. Immunology (2004) 111:241-247.
81. KNOOPS L, RENAULD JC: IL-9 and its receptor: from signal transduction to tumorigenesis. Growth Factors (2004) 22:207-215.
82. HAUBER HP, BERGERON C, HAMID Q: IL-9 in allergic inflammation. Int. Arch. Allergy Immunol. (2004) 134:79-87.
83. STASSEN M, MÜLLER C, ARNOLD M et al.: IL-9 and IL-13 production by activated mast cells is strongly enhanced in the presence of lipopolysaccharide: NF-κB is decisively involved in the expression of IL-9. J. Immunol. (2001) 166:4391-4398.
84. FISCHER M, BIJMAN M, MOLIN D et al.: Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma. Leukemia (2003) 17:2513-2516.
85. ABDELILAH S, LATIFA K, ESRA N et al.: Functional expression of IL-9 receptor by human neutrophils from asthmatic donors: role in IL-8 release. J. Immunol. (2001) 166:2768-2774.
86. DEMOULIN JB, UYTTENHOVE C, LEJEUNE D et al.: STAT5 activation is required for interleukin-9-dependent growth and transformation of lymphoid cells. Cancer Res. (2000) 60:3971-3977.
87. DEMOULIN JB, LOUAHED J, DUMOUTIER L, STEVENS M, RENAULD JC: MAP kinase activation by interleukin-9 in lymphoid and mast cell lines. Oncogene (2003) 22:1763-1770.
88. BARALDO S, FAFFE DS, MOORE PE et al.: Interleukin-9 influences chemokine release in airway smooth muscle: role of ERK. Am. J. Physiol. Lung Cell Mol. Physiol. (2003) 284:L1093-L1102.
89. H2 cytokines. J. Immunol. (2004) 173:113-122.
90. DE SMEDT M, VERHASSELT B, KERRE T et al.: Signals from the IL-9 receptor are critical for the early stages of human intrathymic T cell development. J. Immunol (2000) 164:1761-1767.
91. TOWNSEND JM, FALLON GP, MATTHEWS JD et al.: IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia bur not T cell development. Immunity (2000) 13:573-583.
92. KNOOPS L, LOUAHED J, RENAULD JC: IL-9-induced expansion of B-1b cells restores numbers but not function of B-1 lymphocytes in xid mice. J. Immunol. (2004) 172:6101-6106.
93. PILETTE C, OUADRHIRI Y, VAN SNICK J et al.: IL-9 inhibits oxidative burst and TNF-α release in lipopolysaccharide-stimulated human monocytes through TGF-β. J. Immunol. (2002) 168:4103-4111.
94. MATSUZAWA S, SAKASHITA K, KINOSHITA T et al.: IL-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor. J. Immunol. (2003) 170:3461-3467.
95. READER JR, HYDE DM, SCHELEGLE ES et al.: Interleukin-9 induces mucous cell metaplasia independent of inflammation. Am. J. Resp. Cell. Mol. Biol. (2003) 28:664-672.
96. VERMEER PD, HARSON R, EINWALTER LA, MONINGER T, ZABNER J: Interleukin-9 induces goblet cell hyperplasia during repair of human airway epithelia. Am. J. Resp. Cell. Mol. Biol. (2003) 28:286-295.
97. GOUNNI AS, HAMID Q, RAHMAN SM et al.: IL-9-mediated induction of eotaxin 1/CL11 in human airway smooth muscle cells. J. Immunol. (2004) 173:2771-2779.
98. HAUBER HP, MANOUKIAN JJ, NGUYEN LH et al.: Increased expression of interleukin-9, interleukin-9 receptor, and the calcium-activated chloride channel hCLCA1 in the upper airways of patients with cystic fibrosis. Laryngoscope (2003) 113:1037-1042.
99. FEHNIGER TA, CALIGIURI MA: Interleukin-15: biology and relevance to human disease. Blood (2001) 97:14-32.
100. KUROWSKA M, RUDNICKA W, KONTNY E et al.: Fibroblast-like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bcl-xL and Bcl-2. J. Immunol. (2002) 169:1760-1767.
101. GE N, NISHIOKA Y, NAKAMURA Y et al.: Synthesis and secretion of interleukin-15 by freshly isolated human bronchial epithelial cells. Int. Arch. Allergy Appl. Immunol. (2004) 135:235-242.
102. WALDMANN TA: IL-15 in the life and death of lymphocytes: immunotherapeutic implications. Trends Mol. Med. (2003) 9:517-521.
103. BUDAGIAN V, BULANOVA E, ORINSKA Z et al.: Reverse signaling through membrane-bound interleukin-15. J. Biol. Chem. (2004) 279:42192-42201.
104. NEELY GG, EPELMAN S, MA LL et al.: Monocyte surface-bound IL-15 can function as an activating receptor and participate in reverse signaling. J. Immunol. (2004) 172:4225-4234.
105. BERNARD J, HARB C, MORTIER E et al.: Identification of an interleukin-15α receptor-binding site on human interleukin-15. J. Biol. Chem. (2004) 279:24313-24322.
106. DUBOIS S, MARINER J, WALDMANN TA, TAGAYA Y: IL-15Ra recycles and presents IL-15 in trans to neighboring cells. Immunity (2002) 17:537-547.
107. PARK CS, YOON SO, ARMITAGE RJ, CHOI YS: Follicular dendritic cells produce IL-15 that enhances germinal center B cell proliferation in membrane-bound form. J. Immunol. (2004) 173:6676-6683.
108. SANDAU MM, SCHLUNS KS, LEFRANCOIS L, JAMESON SC: Transpresentation of IL-15 by bone marrow-derived cells necessitates expression of IL-15 and IL-15Rα by the same cells. J. Immunol. (2004) 173:6537-6541.
109. + T cell homeostasis. J. Exp. Med. (2004) 200:825-834.
110. KOBAYASHI H, DUBOIS S, SATO N et al.: Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood (2005) 105:721-727.
111. LODOLCE JP, BURKETT PR, KOKA RM, BOONE DL, MA A: Regulation of lymphoid homeostasis by interleukin-15. Cytokine Growth Factor Rev. (2002) 13:429-439.
112. + T cells. J. Immunol. (2003) 170:5018-5026.
113. + T cells in vitro. Blood (2003) 102:2541-2546.
114. SCHLUNS KS, LEFRANCOIS L: Cytokine control of memory T-cell development and survival. Nat. Rev. Immunol. (2003) 3:269-279.
115. + T cells. Proc. Natl. Acad. Sci. USA (2004) 101:15154-15159.
116. SCHLUNS KS, NOWAK EC, CABRERA-HERNANDEZ A et al.: Distinct cell types control lymphoid subset development by means of IL-15 and IL-15 receptor α expression. Proc. Natl. Acad. Sci. USA (2004) 101:5616-5621.
117. OHTEKI T, SUZUE K, MAKI C, OTA T, KOYASU S: Critical role of IL-15-IL-15R for antigen-presenting cell functions in the innate immune response. Nat. Immunol. (2001) 2:1138-1143.
118. L and Bcl-2. J. Immunol. (2001) 169:1760-1767.
119. MIN SY, HWANG SY, JUNG YO et al.: Increase of cyclooxygenase-2 expression by interleukin-15 in rheumatoid synoviocytes. J. Rheumatol. (2004) 31:875-883.
120. MCINNES IB, GRACIE JA: Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr. Opin. Pharmacol. (2004) 4:392-397.
121. PARRISH-NOVAK J, DILLON SR, NELSON A, HAMMOND A, AL E: Interleukin-21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature (2000) 408:57-63.
122. HABIB T, NELSON A, KAUSHANSKY K: IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses. J. Allergy Clin. Immunol. (2003) 112:1033-1045.
123. SIVAKUMAR PV, FOSTER DC, CLEGG CH: Interleukin-21 is a T-helper cytokine that regulates humoral immunity and cell-mediated anti-tumour responses. Immunology (2004) 112:177-182.
124. STRENGELL M, JULKUNEN I, MATIKAINEN S: IFN-α regulates IL-21 and IL-21R expression in human NK and T cells. J. Leukoc. Biol. (2004) 76:416-422.
125. H1 cells. J. Exp. Med. (2002) 196:969-977.
126. SUTO A, NAKAJIMA H, HIROSE K et al.: Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line Cepsilon transcription of IL-4-stimulated B cells. Blood (2002) 100:4565-4573.
127. H2 effector cells that provide help for B cells. J. Immunol. (2004) 173:68-78.
128. MONTELEONE G, MONTELEONE I, FINA D et al.: Interleukin-21 enhances T-helper cell Type I signaling and interferon-γ production in Crohn's disease. Gastroenterology (2005) 128:687-694.
129. OZAKI K, KIKLY K, MICHALOVICH D, YOUNG PR, LEONARD WJ: Cloning of a Type I cytokine receptor most related to the IL-2 receptor β chain. Proc. Natl. Acad. Sci. USA (2000) 97:11439-11444.
130. JIN H, CARRIO R, YU A, MALEK TR: Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bimdependent apoptosi. J. Immunol. (2004) 173:657-665.
131. BRANDT K, BULFONE-PAUS S, FOSTER DC, RUCKERT R: Interleukin-21 inhibits dendritic cell activation and maturation. Blood (2003) 102:4090-4098.
132. JUNGEL A, DISTLER JH, KUROWSKA-STOLARSKA M et al.: Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum. (2004) 50:1468-1476.
133. KASAIAN MT, WHITTERS MJ, CARTER LL et al.: IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity (2002) 16:559-569.
134. ASAO H, OKUYAMA C, KUMAKI S et al.: The common γ-chain is an indispensable subunit of the IL-21 receptor complex. J. Immunol. (2001) 167:1-5.
135. HABIB T, SENADHEERA S, WEINBERG K, KAUSHANSKY K: The common γ chain (γc) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry (2002) 41:8725-8731.
136. BENNETT F, LUXENBERG D, LING V et al.: Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J. Immunol. (2003) 170:711-718.
137. H1 response. J. Immunol. (2002) 169:3600-3605.
138. STRENGELL M, MATIKAINEN S, SIREN J et al.: IL-21 in synergy with IL-15 or IL-18 enhances IFN-γ production in human NK and T cells. J. Immunol. (2003) 170:5464-5469.
139. + T cells. J. Immunol. (2002) 169:5838-5843.
140. GAMADIA LE, VAN LEEUWEN EM, REMMERSWAAL EB et al.: The size and phenotype of virus-specific T cell populations is determined by repetitive antigenic stimulation and environmental cytokines. J. Immunol. (2004) 172:6107-6114.
141. EBERL M, ENGEL R, BECK E, JOMAA H: Differentiation of human γ-δ T cells towards distinct memory phenotypes. Cell. Immunol. (2002) 218:1-6.
142. + T cell expansion and function. J. Exp. Med. (2005) 201:139-148.
143. + cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur. J. Immunol (2003) 33:3439-3447.
144. WANG G, TSCHOI M, SPOLSKI R et al.: In vivo antitumor activity of interleukin-21 mediated by natural killer cells. Cancer Res. (2003) 63:9016-9022.
145. BRADY J, HAYAKAWA Y, SMYTH MJ, NUTT SL: IL-21 induces the functional maturation of murine NK cells. J. Immunol. (2004) 172:2048-2058.
146. MEHTA DS, WURSTER AL, WHITTERS MJ et al.: IL-21 induces the apoptosis of resting and activated primary B cells. J. Immunol. (2003) 170:4111-4118.
147. OZAKI K, SPOLSKI R, FENG CG et al.: A critical role for IL-21 in regulating immunoglobulin production. Science (2002) 298:1630-1634.
148. HECKER M, BOHNERT A, KONIG IR, BEIN G, HACKSTEIN H: Novel genetic variation of human interleukin-21 receptor is associated with elevated IgE levels in females. Genes Immun. (2003) 4:228-233.
149. PENE J, GAUCHAT JF, LECART S et al.: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells. J. Immunol. (2004) 172:5154-5157.
150. BRENNE AT, BAADE RO T, WAAGE A et al.: Interleukin-21 is a growth and survival factor for human myeloma cells. Blood (2002) 99:3756-3762.
151. BRANDT K, BULFONE-PAUS S, JENCKEL A et al.: Interleukin-21 inhibits dendritic cell-mediated T cell activation and induction of contact hypersensitivity in vivo. J. Invest. Dermatol. (2003) 121:1379-1382.
152. PELLETIER M, BOUCHARD A, GIRARD D: In vivo and in vitro roles of IL-21 in inflammation. J. Immunol. (2004) 173:7521-7530.
153. ROSENBERG SA: Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J. Sci. Am. (2000) 6:S2-S7.
154. FEHNIGER TA, COOPER MA, CALIGIURI MA: Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev. (2002) 13:169-183.
155. MCDERMOTT DF, ATKINS MB: Application of IL-2 and other cytokines in renal cancer. Expert Opin. Biol. Ther. (2004) 4:455-468.
156. CHEN SA, SAWCHUK RJ, BRUNDAGE RC et al.: Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs. J. Pharmacol. Exp. Ther. (2000) 293:248-259.
157. YANG JC, TOPALIAN SL, SCHWARTZENTRUBER DJ et al.: The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A Phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2. Cancer (1995) 76:687-694.
158. SKUBITZ KM, ANDERSON PM: Inhalational interleukin-2 liposomes for pulmonary metastases: a Phase I clinical trial. AntiCancer Drugs (2000) 11:555-563.
159. + T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J. Immunol. (2003) 171:5051-5063.
160. LIU M, ACRES B, BALLOUL JM et al.: Gene-based vaccines and immunotherapeutics. Proc. Natl. Acad. Sci. USA (2004) 101(Suppl.2):14567-14571.
161. REPKA T. CHIOREAN EG, GAY J et al.: Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clin. Cancer Res. (2003) 9:2440-2446.
162. EISENBEIS CF, GRAINGER A, FISCHER B et al.: Combination immunotherapy of B cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and Phase I study. Clin. Cancer Res. (2004) 10:6101-6110.
163. CASSELL DJ, CHOUDHRI S, HUMPHREY R et al.: Therapeutic enhancement of IL-2 through molecular design. Curr Pharm Des (2002) 8:2171-2183.
164. BALUNA R, RIZO J, GORDON BE, GHETIE V, VITETTA ES: Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc. Natl. Acad. Sci. USA (1999) 96:3957-3962.
165. SMALLSHAW JE, GHETIE V, RIZO J et al.: Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nat. Biotechnol. (2003) 21:387-391.
166. ECKENBERG R, ROSE T, MOREAU JL et al.: Characterization of an IL-2 mimetic with therapeutic potential. Cell. Mol. Biol. (2001) 47:703-707.
167. ROSE T, MOREAU JL, ECKENBERG R, THEZE J: Structural analysis and modeling of a synthetic interleukin-2 mimetic and its interleukin-2Rβ2 receptor. J. Biol. Chem. (2003) 278:22868-22876.
168. EPSTEIN AL, MIZOKAMI MM, LI J, HU P, KHAWLI LA: Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J. Natl. Cancer Inst. (2003) 95:741-749.
169. HU P, MIZOKAMI M, RUOFF G, KHAWLI LA, EPSTEIN AL: Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity. Blood (2003) 101:4853-4861.
170. CARSON WE, YU H, DIERKSHEIDE J et al.: A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells. J. Immunol. (1999) 162:4943-4951.
171. ASSIER E, JULLIEN V, LEFORT J et al.: NK cells and polymorphonuclear neutrophils are both critical for IL-2-induced pulmonary vascular leak syndrome. J. Immunol. (2004) 172:7661-7668.
172. SHANAFELT AB, LIN Y, SHANAFELT MC et al.: A T-cell-selective interleukin-2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nat Biotechnol (2000) 18:1197-1202.
173. MARGOLIN KA, ATKINS MB, WEBER J et al.: Phase I study of interleukin-2 (IL-2) selective agonist BAY 50-4798 (BAY) in patients (pts.) with advanced melanoma (Mel) and renal cell carcinoma (RCC). ASCO Annual Meeting (2002) Abstract 46.
174. MATTHEWS L, CHAPMAN S, RAMCHANDANI MS et al.: BAY 50-4798, a novel, high-affinity receptor-specific recombinant interleukin-2 analog, induces dose-dependent increases in CD25 expression and proliferation among unstimulated, human peripheral blood mononuclear cells in vitro. Clin. Immunol. (2004) 113:248-255.
175. FEHNIGER TA, COOPER MA, NUOVO GJ et al.: CD56 bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood (2003) 101:3052-3057.
176. RAO BM, GIRVIN AT, CIARDELLI T, LAUFFENBURGER DA, WITTRUP KD: Interleukin-2 mutants with enhanced α-receptor subunit binding affinity. Protein Engl. (2003) 16:1081-1087.
177. RAO BM, DRIVER I, LAUFFENBURGER DA, WITTRUP KD: Interleukin 2 (IL-2) variants engineered for increased IL-2 receptor α-subunit affinity exhibit increased potency arising from a cell surface ligand reservoir effect. Mol. Pharmacol. (2004) 66:864-869.
178. DAVIS CB, GILLIES SD: Immunocytokines: amplification of anticancer immunity. Cancer Immunol. Immunother. (2003) 52:297-308.
179. GILLIES SD, LO KM, BURGER C et al.: Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis. Clin. Cancer Res. (2002) 8:210-216.
180. KING DM, ALBERTINI MR, SCHALCH H et al.: Phase I cinical trial of the immunocytokine EMD 273063 in melanoma patients. J. Clin. Oncol. (2004) 15:4463-4473.
181. KO YJ, BUBLEY GJ, WEBER R et al.: Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a Phase I trial in patients with prostate cancer. J. Immunother. (2004) 27:232-239.
182. YAO Z, DAI W, PERRY J, BRECHBIEL MW, SUNG C: Effect of albumin fusion on the biodistribution of interleukin-2. Cancer Immunol. Immunother. (2004) 53:404-410.
183. MELDER RJ, OSBORN BL, RICCOBENE T et al.: Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice. Cancer Immunol. Immunother. in press.
184. DUDLEY ME, ROSENBERG SA: Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer (2003) 3:666-675.
185. LIU K, ROSENBERG SA: Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent. J. Immunother. (2003) 26:190-201.
186. LU J, GIUNTOLI RL, OMIYA R et al.: Interleukin-15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin. Cancer Res. (2002) 8:3877-3884.
187. BRENTJENS RJ, LATOUCHE JB, SANTOS E et al.: Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. (2003) 9:279-286.
188. + T cells. Proc. Natl. Acad. Sci. USA (2004) 101:1969-1974.
189. MUNGER W, DEJOY SQ, JEYASEELAN RS et al.: Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell. Immunol. (1995) 165:289-293.
190. MA HL, WHITTERS MJ, KONZ RF et al.: IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-γ. J. Immunol. (2003) 171:608-615.
191. DI CARLO E, COMES A, ORENGO AM et al.: IL-21 induces tumor rejection by specific CTL and IFN-γ-dependent CXC chemokines in syngeneic mice. J. Immunol. (2004) 172:1540-1547.
192. + T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15 and IL-21. J. Immunol. (2004) 173:900-909.
193. PETT SL, KELLEHER AD: Cytokine therapies in HIV-1 infection: present and future. Expert Rev. Anti Infect Ther. (2003) 1:83-96.
194. VAN DEN BRINK MR, ALPDOGAN O, BOYD RL: Strategies to enhance T-cell reconstitution in immunocompromised patients. Nat. Rev. Immunol. (2004) 4:856-867.
195. ALPDOGAN O, VAN DEN BRINK MR: IL-7 and IL-15: therapeutic cytokines for immunodeficiency. Trends Immunol. (2005) 26:56-64.
196. PAU AK, TAVEL JA: Therapeutic use of interleukin-2 in HIV-infected patients. Curr. Opin. Pharmacol. (2002) 2:433-439.
197. + T cells in vivo after IL-2 treatment of patients with HIV infection. Proc. Natl. Acad. Sci. USA (2002) 99:10712-10717.
198. LEVY Y, DURIER C, KRZYSIEK R et al.: Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS (2003) 17:343-351.
199. FAREL CE, CHAITT DG, HAHN BK et al.: Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. Blood (2004) 104:3282-3286.
200. MARTINEZ-MARINO B, SHIBOSKI S, HECHT FM, KAHN JO, LEVY JA: Interleukin-2 therapy restores CD8 cell non-cytotoxic anti-HIV responses in primary infection subjects receiving HAART. AIDS (2004) 18:1991-1999.
201. FRY TJ, MONIUSZKO M, CREEKMORE S et al.: IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood (2003) 101:2294-2299.
202. + T cells in vivo. J. Virol. (2004) 78:9740-9749.
203. WANG FX, XU Y, SULLIVAN J et al.: IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J. Clin. Invest. (2005) 115:128-137.
204. MASTROIANNI CM, D'ETTORRE G, FORCINA G, VULLO V: Teaching tired T cells to fight HIV: time to test IL-15 for immunotherapy? Trends Immunol. (2004) 25:121-125.
205. CHITNIS V, PAHWA R, PAHWA S: Determinants of HIV-specific CD8 T-cell responses in HIV-infected pediatric patients and enhancement of HIV-gag-specific responses with exogenous IL-15. Clin. Immunol. (2003) 107:36-45.
206. FORCINA G, D'ETTORRE G, MASTROIANNI CM et al.: Interleukin-15 modulates interferon-γ and β-chemokine production in patients with HIV infection: implications for immune-based therapy. Cytokine (2004) 25:283-290.
207. LUM JJ, SCHNEPPLE DJ, NIE Z et al.: Differential effects of interleukin-7 and interleukin-15 on NK cell anti-human immunodeficiency virus activity. J. Virol. (2004) 78:6033-6042.
208. BERZOFSKY JA, AHLERS JD, JANIK J et al.: Progress on new vaccine strategies against chronic viral infections. J. Clin. Invest. (2004) 114:450-462.
209. BERZOFSKY JA, TERABE M, OH S et al.: Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J. Clin. Invest. (2004) 113:1515-1525.
210. ROSENBERG SA, YANG JC, SCHWARTZENTRUBER DJ et al.: Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J. Immunol. (1999) 163:1690-1695.
211. OH S, BERZOFSKY JA, BURKE DS, WALDMANN TA, PERERA LP: Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc. Natl. Acad. Sci. USA (2003) 100:3392-3397.
212. VILLINGER F, MILLER R, MORI K et al.: IL-15 is superior to IL-2 in the generation of long-lived antigen specific memory CD4 and CD8 T cells in rhesus macaques. Vaccine (2004) 22:3510-3521.
213. CUI FD, ASADA H, JIN ML et al.: Cytokine genetic adjuvant facilitates prophylactic intravascular DNA vaccine against acute and latent herpes simplex virus infection in mice. Gene Ther. (2005) 12:160-168.
214. FIGDOR CG, DE VRIES IJ, LESTERHUIS WJ, MELIEF CJ: Dendritic cell immunotherapy: mapping the way. Nat. Med. (2004) 10:475-480.
215. SAIKH KU, KHAN AS, KISSNER T, ULRICH RG: IL-15-induced conversion of monocytes to mature dendritic cells. Clin. Exp. Immunol. (2001) 126:447-455.
216. MOHAMADZADEH M, BERARD F, ESSERT G et al.: Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J. Exp. Med. (2001) 194:1013-1020.
217. + Tc1 responses in vivo. Eur. J. Immunol. (2004) 34:66-73.
218. FERLAZZO G, PACK M, THOMAS D et al.: Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc. Natl. Acad. Sci. USA (2004) 101:16606-16611.
219. H2 cells in inflammatory disease states: therapeutic implications. Expert Opin. Biol. Ther. (2004) 3:1887-1896.
220. ADORINI L: Cytokine-based immunointervention in the treatment of autoimmune diseases. Clin. Exp. Immunol. (2003) 132:185-192.
221. H2 responses and improves human autoimmune disease. Nat. Med. (2003) 9:40-46.
222. MARTIN R: Interleukin-4 treatment of psoriasis: are pleiotropic cytokines suitable therapies for autoimmune diseases? Trends Pharmacol. Sci. (2003) 24:613-616.
223. + T cell-defective IL-4 production in the non-obese diabetic mouse. Int. Immunol. (1996) 8:1751-1758.
224. SHARIF S, ARREAZA GA, ZUCKER P et al.: Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat. Med. (2001) 7:1057-1062.
225. VOLLMER TL, LIU R, PRICE M et al.: Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J. Immunol. (2005) 174:2696-2701.
226. VON DER THUSEN JH, VAN BERKEL TJ, BIESSEN EA: Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Circulation (2001) 103:1164-1170.
227. VOS DER THUSEN JH, KUIPER J, VAN BERKEL TJ, BIESSEN EA: Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol. Rev. (2003) 55:133-166.
228. DUMONT FJ: Immunosuppressive strategies for prevention of transplant rejection. Expert Opin. Ther. Patents (2001) 11:377-404.
229. HOGAN PG, CHEN L, NARDONE J, RAO A: Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev. (2003) 17:2205-2232.
230. 2+ channels and T-lymphocyte activation by the pyrazole derivative BTP2. J. Biol. Chem. (2004) 279:12427-12437.
231. H2 cytokine inhibition by 3,5-bis(trifluoromethyl)pyrazoles, a novel class of immunomodulators. Cell. Immunol. (2002) 220:134-142.
232. MORRIS JS, WALDMANN TA: Advances in interleukin 2 receptor targeted treatment. Ann. Rheum. Dis. (2000) 59(Suppl. 1):109-114.
233. ROWSHANI AT: USS A, YONG SL, VAN LIER RA, TEN BERGE IJ: Effects of CD25 monoclonal antibody on proliferative and effector functions of alloactivated human T cells in vitro. Eur. J. Immunol. (2004) 34:882-899.
234. CIBRIK DM, KAPLAN B, MEIER-KRIESCHE HU: Role of anti-interleukin-2 receptor antibodies in kidney transplantation. BioDrugs (2001) 15:555-566.
235. CREED TJ, NORMAN MR, PROBERT CS et al.: Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment. Pharmacol. Ther. (2003) 18:65-75.
236. BIELEKOVA B, RICHERT N, HOWARD T et al.: Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon-β. Proc. Natl. Acad. Sci. USA (2004) 101:9705-9708.
237. OWEN CM, HARRISON PV: Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody. Clin. Exp. Dermatol. (2000) 25:195-197.
238. NUSSENBLATT RB, THOMPSON DJ, LI Z et al.: Humanized anti-interleukin-2 (IL-2) receptor α therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J. Autoimmun. (2003) 21:283-293.
239. BAUDOUIN V, CRUSIAUX A, HADDAD E et al.: Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation (2003) 76:459-463.
240. HYDE J, BRAISTED AC, RANDAL M, ARKIN MR: Discovery and characterization of cooperative ligand binding in the adaptive region of interleukin-2. Biochemistry (2003) 42:6475-6483.
241. RAIMUNDO BC, OSLOB JD, BRAISTED AC et al.: Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: an approach for inhibiting protein-protein interactions. J. Med. Chem. (2004) 47:3111-3130.
242. WAAL ND, YANG W, OSLOB JD et al.: Identification of nonpeptidic small-molecule inhibitors of interleukin-2. Bioorg. Med. Chem. Lett (2005) 15:983-987.
243. RUCKERT R, ASADULLAH K, SEIFERT M et al.: Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis? J. Immunol. (2000) 165:2240-2250.
244. GREEN PH, JABRI B: Coeliac disease. Lancet (2003) 362:383-391.
245. + intraepithelial lymphocytes in organ cultures of treated celiac patients. Am. J. Gastroenterol. (2001) 96:150-156.
246. ROBERTS AI, LEE L, SCHWARZ E et al.: NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J. Immunol. (2001) 167:5527-5530.
247. HUE S, MENTION JJ, MONTEIRO RC et al.: A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity (2004) 21:367-377.
248. MERESSE B, CHEN Z, CISZEWSKI C et al.: Coordinated induction by IL-15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity (2004) 21:357-366.
249. GROH V, BRUHL A, EL-GABALAWY H, NELSON JL, SPIES T: Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA (2003) 100:9452-9457.
250. PETTIT DK, BONNERT TP, EISENMAN J et al.: Structure-function studies of interleukin-15 using site-specific mutagenesis, polyethylene glycol conjugation, and homology modeling. J. Biol. Chem. (1997) 272:2312-2318.
251. KIM YS, MASLINSKI W, ZHENG XX et al.: Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fcγ2a protein blocks delayed-type hypersensitivity. J. Immunol. (1998) 160:5742-5748.
252. FERRARI-LACRAZ S, ZHENG XX, KIM YS et al.: An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection. J. Immunol. (2001) 167:3478-3485.
253. ZHENG XX, SANCHEZ-FUEYO A, SHO M et al.: Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity (2003) 19:503-514.
254. FERRARI-LACRAZ S, ZANELLI E, NEUBERG M et al.: Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J. Immunol. (2004) 173:5818-5826.
255. SMITH XG, BOLTON EM, RUCHATZ H et al.: Selective blockade of IL-15 by soluble IL-15 receptor α-chain enhances cardiac allograft survival. J. Immunol. (2000) 165:3444-3450.
256. BUDAGIAN V, BULANOVA E, ORINSKA Z et al.: Natural soluble interleukin-15Rα is generated by cleavage that involves the tumor necrosis factor-α-converting enzyme (TACE/ADAM17). J. Biol. Chem. (2004) 279:40368-40375.
257. MORTIER E, BERNARD J, PLET A, JACQUES Y: Natural, proteolytic release of a soluble form of human IL-15 receptor α-chain that behaves as a specific, high affinity IL-15 antagonist. J. Immunol. (2004) 173:1681-1688.
258. VILLADSEN LS, SCHUURMAN J, BEURSKENS F et al.: Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J. Clin. Invest. (2003) 112:1571-1580.
259. MCINNES I, MARTIN R, ZIMMERMAN-GORSKA I et al.: Safety and efficacy of a human monoclonal antibody to IL-15 (AMG 714) in patients with rheumatoid arthritis (RA): results from a multicenter, randomized, double-blind, placebo-controlled trial. ACR Meeting (2004) 527.
260. DISTLER JH, JUNGEL A, KOWAL-BIELECKA O et al.: Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum. (2005) 52:856-864.
261. BORISH LC, NELSON HS, CORREN J et al.: Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. (2001) 107:963-970.
262. HARRIS P, LINDELL D, FITCH N, GUNDEL R: The IL-4 receptor antagonist (Bay 16-9996) reverses airway hyperresponsiveness in a primate model of asthma. Am. J. Resp. Crit. Care Med. (1999) 159:A230.
263. NISHIKUBO K, MURATA Y, TAMAKI S et al.: A single administration of interleukin-4 antagonistic mutant DNA inhibits allergic airway inflammation in a mouse model of asthma. Gene Ther. (2003) 10:2119-2125.
264. LAPORTE SL, FORSYTH CM, CUNNINGHAM BC et al.: De novo design of an IL-4 antagonist and its structure at 1.9 Å. Proc Natl. Acad. Sci. USA (2005) 102:1889-1894.
265. PFITZNER E, KLIEM S, BAUS D, LITTERST CM: The role of STATs in inflammation and inflammatory diseases. Curr. Pharm. Des. (2004) 10:2839-2850.
266. WANG Y, MALABARBA MG, NAGY ZS, KIRKENM RA: Interleukin 4 regulates phosphorylation of serine 756 in the transactivation domain of Stat6. Roles for multiple phosphorylation sites and Stat6 function. J. Biol. Chem. (2004) 279:25196-25203.
267. SUMI K, YOKOZEKI H, WU MH et al. In vivo transfection of a cis element 'decoy' against signal transducers and activators of the transcription 6 (STAT6) binding site ameliorates the response of contact hypersensitivity. Gene Ther. (2004) 11:1763-1771.
268. YOKOZEKI H, WU MH, SUMI K et al.: In vivo transfection of a cis element 'decoy' against signal transducers and activators of transcription 6 (STAT6)-binding site ameliorates IgE-mediated late-phase reaction in an atopic dermatitis mouse model. Gene Ther. (2004) 11:1753-1762.
269. DANAHAY H, HILL S, NATT F, OWEN CE: The in vitro and in vivo pharmacology of antisense oligonucleotides targeted to murine Stat6. Inflamm. Res. (2000) 49:692-699.
270. SAKURAI M, NISHIO M, YAMAMOTO K et al.: TMC-264, a novel antiallergic heptaketide produced by the fungus Phoma sp. TC 1674. Org. Lett. (2003) 5:1083-1085.
271. SAKURAI M, NISHIO M, YAMAMOTO K et al.: TMC-264, a novel inhibitor of STAT6 activation produced by Phoma sp. TC 1674. J. Antibiot. (Tokyo) (2003) 56:513-519.
272. RAZETO A, RAMAKRISHNAN V, LITTERST CM et al.: Structure of the NCoA-1/SRC-1 PAS-B domain bound to the LXXLL motif of the STAT6 transactivation domain. J. Mol. Biol. (2004) 336:319-329.
273. YING S, MENG Q, KAY AB, ROBINSON DS: Elevated expression of interleukin-9 mRNA in the bronchial mucosa of atopic asthmatics and allergen-induced cutaneous late-phase reaction: relationships to eosinophils, mast cells and T lymphocytes. Clin. Exp. Allergy (2002) 32:866-871.
274. TODA M, TULIC MK, LEVITT RC, HAMID Q: A calcium-activated chloride channel (HCLCA1) is strongly related to IL-9 expression and mucus production in bronchial epithelium of patients with asthma. J. Allergy Clin. Immunol. (2002) 109:246-250.
275. ERPENBECK VJ, HOHLFELD JM, VOLKMANN B et al.: Segmental allergen challenge in patients with atopic asthma leads to increased IL-9 expression in bronchoalveolar lavage fluid lymphocytes. J. Allergy Clin. Immunol. (2003) 111:1319-1327.
276. H2 cytokine expression, leading to immune pathology. J. Clin. Invest. (2002) 109:29-39.
277. KUNG TT, LUO B, CRAWLEY Y et al.: Effect of anti-mIL-9 antibody on the development of pulmonary inflammation and airway hyperresponsiveness in allergic mice. Am. J. Respir. Cell Mol. Biol. (2001) 25:600-605.
278. CHENG G, ARIMA M, HONDA K et al.: Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am. J. Resp. Crit. Care Med. (2002) 166:409-416.
279. OLOSZ F, MALEK TR: Structural basis for binding multiple ligands by the common cytokine receptor γ-chain. J. Biol. Chem. (2002) 277:12047-12052.
280. ZHANG JL, FOSTER D, SEBALD W: Human IL-21 and IL-4 bind to partially overlapping epitopes of common γ-chain. Biochem. Biophys. Res. Commun. (2003) 300:291-296.
281. RASKIN N, JAKUBOWSKI A, SIZING ID et al.: Molecular mapping with functional antibodies localizes critical sites on the human IL receptor common γ (γc) chain. J. Immunol. (1998) 161:3474-3483.
282. MEISSNER U, BLUM H, SCHNARE M, ROLLINGHOFF M, GESSNER A: A soluble form of the murine common γ chain is present at high concentrations in vivo and suppresses cytokine signaling. Blood (2001) 97:183-191.
283. NISHIO J, KOHSAKA H, SHIMAMURA T, HAMURO J, MIYASAKA N: Abundant expression of common cytokine receptor γ chain (CD132) in rheumatoid joints. J. Rheumatol. (2001) 28:240-244.
284. O'SHEA JJ, HUSA M, LI D et al.: Jak3 and the pathogenesis of severe combined immunodeficiency. Mol. Immunol. (2004) 41:727-737.
285. BORIE DC, O'SHEA JJ, CHANGELLAN PS: JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants. Trends Mol. Med. (2004) 10:532-541.
286. PODDER H, KAHAN BD: Janus kinase 3: a novel target for selective transplant immunosupression. Expert Opin. Ther. Targets (2004) 8:613-629.
287. CETKOVIC-CVRLJE M, DRAGT AL, VASSILEV A, LIU XP, UCKUN FM: Targeting JAK3 with JANEX-1 for prevention of autoimmune Type 1 diabetes in NOD mice. Clin. Immunol. (2003) 106:213-225.
288. CHANGELIAN PS, FLANAGAN ME, BALL DJ, AL E: Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science (2003) 302:875-878.
289. + cell numbers in cynomolgus monkey blood following chronic oral dosing. J. Leukoc. Biol. (2004) 76:1248-1255.
290. MESTAS J, HUGHES CC: Of mice and not men: differences between mouse and human immunology. J. Immunol. (2004) 172:2731-2738.
291. + T cells. Blood (2002) 100:2159-2167.
292. + T regulatory cells, immunotherapy of cancer, and interleukin-2. J. Immunother. (2005) 28:120-128.
293. SLEBOS DJ, KAUFFMAN HF, KOETER GH et al.: Airway cellular response to two different immunosuppressive regimens in lung transplant recipients. Clin. Transplant. (2005) 19:243-249.
294. NISSIM A, GOFUR Y, VESSILLIER S, ADAMS G, CHERNAJOVSKY Y: Methods for targeting biologicals to specific disease sites. Trends Mol. Med. (2004) 10:269-274.
295. KOVARIK JM, BURTIN P: Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases. Expert Opin. Emerg. Drugs (2003) 8:47-62.
296. BOUSSIOTIS VA, BARBER DL, NAKARAI T et al.: Prevention of T cell anergy by signaling through the γc chain of the IL-2 receptor. Science (1994) 266:1039-1042.
297. BARATA JT, KEENAN TD, SILVA A et al.: Common γ chain-signaling cytokines promote proliferation of T-cell acute lymphoblastic leukemia. Haematologica (2004) 89:1459-1467.
298. KOVANEN PE, ROSENWALD A, FU J et al.: Analysis of γc-family cytokine target genes. Identification of dual-specificity phosphatase 5 (DUSP5) as a regulator of mitogen-activated protein kinase activity in interleukin-2 signaling. J. Biol. Chem. (2003) 278:5205-5213.